03.06.2024
Egnach, June 3, 2024 – After the countries of Switzerland, Austria and Germany are opened up, the tinniwell is introduced in the Britain and France markets. With an average number of approx. 15% tinnitus affected by the population, there is a market potential of around 20 million patients. This means more than double the sales of the tinniwell in Europe.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 714500668